Cargando…
One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches
Exocrine pancreatic neoplasms represent up to 95% of pancreatic cancers (PCs) and are widely recognized among the most lethal solid cancers, with a very poor 5-year survival rate of 5%-10%. The remaining < 5% of PCs are neuroendocrine tumors that are usually characterized by a better prognosis, w...
Autores principales: | Niger, Monica, Prisciandaro, Michele, Antista, Maria, Monica, Melissa Anna Teresa, Cattaneo, Laura, Prinzi, Natalie, Manglaviti, Sara, Nichetti, Federico, Brambilla, Marta, Torchio, Martina, Corti, Francesca, Pusceddu, Sara, Coppa, Jorgelina, Mazzaferro, Vincenzo, de Braud, Filippo, Di Bartolomeo, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443847/ https://www.ncbi.nlm.nih.gov/pubmed/32879662 http://dx.doi.org/10.4251/wjgo.v12.i8.833 |
Ejemplares similares
-
The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence
por: Pusceddu, Sara, et al.
Publicado: (2020) -
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Pusceddu, Sara, et al.
Publicado: (2019) -
Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors
por: Pusceddu, Sara, et al.
Publicado: (2020) -
Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan
por: Pietrantonio, Filippo, et al.
Publicado: (2020) -
Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study
por: Pusceddu, Sara, et al.
Publicado: (2021)